表紙
市場調查報告書

全球前列腺肥大症(BPH)治療藥市場:市場機會分析與產業預測 2018年∼2025年

Benign Prostatic Hyperplasia Therapeutics Market by Therapeutic Class, and Therapy - Global Opportunity Analysis and Industry Forecast, 2018-2025

出版商 Allied Market Research 商品編碼 677070
出版日期 內容資訊 英文 205 Pages
商品交期: 2-3個工作天內
價格
全球前列腺肥大症(BPH)治療藥市場:市場機會分析與產業預測 2018年∼2025年 Benign Prostatic Hyperplasia Therapeutics Market by Therapeutic Class, and Therapy - Global Opportunity Analysis and Industry Forecast, 2018-2025
出版日期: 2018年07月01日內容資訊: 英文 205 Pages
簡介

全球前列腺肥大症(BPH)治療藥市場,2017年價值106億8,872萬美元,預計從2018年到2025年以8.1%的年複合成長率發展,成長到2025年200億9,668萬美元規模的市場。這個市場的主要成長要素,是男性老年人的增加。

本報告提供全球前列腺肥大症(BPH)治療藥市場調查,市場概要,各治療藥、治療方法、地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,市場規模,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

第2章 摘要整理

  • 調查結果
  • CXO的觀點

第3章 市場概況

  • 市場定義和範圍
  • 主要的觀察
  • 前幾名企業的市場定位
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係
  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 影響分析
  • 臨床試驗

第4章 全球前列腺肥大症(BPH)治療藥市場:各治療藥物

  • 概要
    • 市場規模的變化與預測
  • 交感神經α受體阻斷劑
    • 主要的市場趨勢,成長要素,市場機會
    • 市場規模的變化與預測:各地區
    • 市場分析:各國
  • 5α-還原酵素抑制劑(5-ARIs)
    • 主要的市場趨勢,成長要素,市場機會
    • 市場規模的變化與預測:各地區
    • 市場分析:各國
  • PDE5抑制劑
    • 主要的市場趨勢,成長要素,市場機會
    • 市場規模的變化與預測:各地區
    • 市場分析:各國
  • 其他
    • 主要的市場趨勢,成長要素,市場機會
    • 市場規模的變化與預測:各地區
    • 市場分析:各國

第5章 全球前列腺肥大症(BPH)治療藥市場:各治療法

  • 概要
    • 市場規模的變化與預測
  • 單劑療法
    • 市場規模的變化與預測:各地區
    • 市場分析:各國
  • 多劑聯合治療
    • 市場規模的變化與預測:各地區
    • 市場分析:各國

第6章 全球前列腺肥大症(BPH)治療藥市場:各地區

  • 概要
    • 市場規模的變化與預測
  • 北美
    • 主要的市場趨勢,成長要素,市場機會
    • 市場規模的變化與預測:各國
    • 市場規模的變化與預測:各治療藥物
    • 市場規模的變化與預測:各治療法
  • 歐洲
    • 主要的市場趨勢,成長要素,市場機會
    • 市場規模的變化與預測:各國
    • 市場規模的變化與預測:各治療藥物
    • 市場規模的變化與預測:各治療法
  • 亞太地區
    • 主要的市場趨勢,成長要素,市場機會
    • 市場規模的變化與預測:各國
    • 市場規模的變化與預測:各治療藥物
    • 市場規模的變化與預測:各治療法
  • 南美、中東、非洲
    • 主要的市場趨勢,成長要素,市場機會
    • 市場規模的變化與預測:各國
    • 市場規模的變化與預測:各治療藥物
    • 市場規模的變化與預測:各治療法

第7章 企業簡介

  • Abbott Laboratories
  • Allergan plc
  • Astellas Pharma Inc.
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Limited
目錄
Product Code: LI_184708

Title:
Benign Prostatic Hyperplasia Therapeutics Market by Therapeutic Class (Alpha Blocker, 5- Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, and Others), and Therapy (Mono Drug Therapy and Combination Drug Therapy) - Global Opportunity Analysis and Industry Forecast, 2018-2025 .

The prostate is a walnut-sized gland that surrounds the urethra in the male reproductive system. The main function of this gland is to secrete a fluid, which mixes with the fluids from other glands and sperm cells from the testicles to generate semen. Benign prostatic hyperplasia (BPH) is a non-malignant increase in the size of the prostate gland. This increase blocks the urine flow from the bladder, which results in increased urination frequency at night, urinary hesitancy, and urinary retention. BPH significantly influences the patient's quality of life, owing to symptoms, such as urine leakage and nocturia. If untreated for a long duration, it results in more serious health issues, such as bladder damage, bladder stones, kidney damage, and urinary tract infections (UTIs).

The global benign prostatic hyperplasia therapeutics market was valued at $10,688.72 million in 2017, and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025. This market is majorly driven by an increase in the male geriatric population because the disease generally occurs in men of age 60 and above. The other factors boosting the market growth include growth in awareness related to urological disorders and prostate cancer and rise in the number of global benign prostatic hyperplasia patients. However, preferences for minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hinder the growth of the global BPH therapeutics market. Furthermore, presence of a plethora of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities during the forecast period.

The global benign prostatic hyperplasia therapeutics market is segmented into therapeutic class, therapy, and region. On the basis of therapeutic class, the market is categorized into alpha blocker, 5-alpha reductase inhibitor, phosphodiesterase-5 inhibitor, and others. As per therapy, the market is bifurcated into mono drug therapy and combination drug therapy. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America Middle East and Africa (LAMEA).

KEY BENEFITS

  • The study provides an in-depth analysis of the global benign prostatic hyperplasia therapeutics market with current trends and future estimations from 2017 to 2025 to elucidate the imminent investment pockets.
  • A comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on global and regional scales are provided.
  • The profiles of key players and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
  • Key market segments

By Therapeutic Class

  • Alpha blocker
  • 5-Alpha reductase inhibitor
  • Phosphodiesterase-5 inhibitor
  • Others

By Therapy

  • Mono drug therapy
  • Combination drug therapy

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Abbott Laboratories
  • Allergan plc
  • Astellas Pharma, Inc.
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Limited

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits for stakeholders
  • 1.3. Key market segments
    • 1.3.1. List of key players profiled in the report
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. Key findings of the study
  • 2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets
  • 3.3. Top player positioning, 2017
  • 3.4. Porters Five Forces analysis
    • 3.4.1. Bargaining power of buyers
    • 3.4.2. Bargaining power of suppliers
    • 3.4.3. Threat of substitution
    • 3.4.4. Threat of new entrant
    • 3.4.5. Competitive rivalry
  • 3.5. Market dynamics
    • 3.5.1. Drivers
      • 3.5.1.1. Rise in in geriatric population
      • 3.5.1.2. Rise in prevalence of benign prostatic hyperplasia
      • 3.5.1.3. Growth in the awareness related to urological disorders and prostate cancer
    • 3.5.2. Restraints
      • 3.5.2.1. High preferences for minimally invasive surgical therapies
    • 3.5.3. Opportunities
      • 3.5.3.1. Large number of products in pipeline
      • 3.5.3.2. Opportunities in emerging economies
    • 3.5.4. Impact analyses
  • 3.6. Clinical trials

CHAPTER 4: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Alpha Blockers
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market analysis, by country
  • 4.3. 5-Alpha Reductase Inhibitors
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market analysis, by country
  • 4.4. Phosphodiesterase 5 Inhibitor
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market analysis, by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market analysis, by country

CHAPTER 5: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Mono Drug Therapy
    • 5.2.1. Market size and forecast, by region
    • 5.2.2. Market analysis, by country
  • 5.3. Combination Drug Therapy
    • 5.3.1. Market size and forecast, by region
    • 5.3.2. Market analysis, by country

CHAPTER 6: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. North America benign prostatic hyperplasia therapeutics market, by country
      • 6.2.2.1. U.S.
      • 6.2.2.1.1. Market size and forecast, by therapeutic class
      • 6.2.2.1.2. Market size and forecast, by therapy
      • 6.2.2.2. Canada
      • 6.2.2.2.1. Market size and forecast, by therapeutic class
      • 6.2.2.2.2. Market size and forecast, by therapy
      • 6.2.2.3. Mexico
      • 6.2.2.3.1. Market size and forecast, by therapeutic class
      • 6.2.2.3.2. Market size and forecast, by therapy
    • 6.2.3. North America market size and forecast, by therapeutic class
    • 6.2.4. North America market size and forecast, by therapy
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Europe market size and forecast, by country
      • 6.3.2.1. Germany
      • 6.3.2.1.1. Market size and forecast, by therapeutic class
      • 6.3.2.1.2. Market size and forecast, by therapy
      • 6.3.2.2. France
      • 6.3.2.2.1. Market size and forecast, by therapeutic class
      • 6.3.2.2.2. Market size and forecast, by therapy
      • 6.3.2.3. UK
      • 6.3.2.3.1. Market size and forecast, by therapeutic class
      • 6.3.2.3.2. Market size and forecast, by therapy
      • 6.3.2.4. Italy
      • 6.3.2.4.1. Market size and forecast, by therapeutic class
      • 6.3.2.4.2. Market size and forecast, by therapy
      • 6.3.2.5. Spain
      • 6.3.2.5.1. Market size and forecast, by therapeutic class
      • 6.3.2.5.2. Market size and forecast, by therapy
    • 6.3.3. Rest of Europe
      • 6.3.3.1.1. Market size and forecast, by therapeutic class
      • 6.3.3.1.2. Market size and forecast, by therapy
    • 6.3.4. Europe market size and forecast, by therapeutic class
    • 6.3.5. Europe market size and forecast, by therapy
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Asia-Pacific market size and forecast, by country
      • 6.4.2.1. Japan
      • 6.4.2.1.1. Market size and forecast, by therapeutic class
      • 6.4.2.1.2. Market size and forecast, by therapy
      • 6.4.2.2. China
      • 6.4.2.2.1. Market size and forecast, by therapeutic class
      • 6.4.2.2.2. Market size and forecast, by therapy
      • 6.4.2.3. India
      • 6.4.2.3.1. Market size and forecast, by therapeutic class
      • 6.4.2.3.2. Market size and forecast, by therapy
      • 6.4.2.4. Australia
      • 6.4.2.4.1. Market size and forecast, by therapeutic class
      • 6.4.2.4.2. Market size and forecast, by therapy
      • 6.4.2.5. South Korea
      • 6.4.2.5.1. Market size and forecast, by therapeutic class
      • 6.4.2.5.2. Market size and forecast, by therapy
      • 6.4.2.6. Rest of Asia-Pacific
      • 6.4.2.6.1. Market size and forecast, by therapeutic class
      • 6.4.2.6.2. Market size and forecast, by therapy
    • 6.4.3. Asia-Pacific market size and forecast, by therapeutic class
    • 6.4.4. Asia-Pacific market size and forecast, by therapy
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. LAMEA market size and forecast, by country
      • 6.5.2.1. Brazil
      • 6.5.2.1.1. Market size and forecast, by therapeutic class
      • 6.5.2.1.2. Market size and forecast, by therapy
      • 6.5.2.2. Saudi Arabia
      • 6.5.2.2.1. Market size and forecast, by therapeutic class
      • 6.5.2.2.2. Market size and forecast, by therapy
      • 6.5.2.3. South Africa
      • 6.5.2.3.1. Market size and forecast, by therapeutic class
      • 6.5.2.3.2. Market size and forecast, by therapy
      • 6.5.2.4. Rest of LAMEA
      • 6.5.2.4.1. Market size and forecast, by therapeutic class
      • 6.5.2.4.2. Market size and forecast, by therapy
    • 6.5.3. LAMEA market size and forecast, by therapeutic class
    • 6.5.4. LAMEA market size and forecast, by therapy

CHAPTER 7: COMPANY PROFILES

  • 7.1. Abbott Laboratories
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Operating business segments
    • 7.1.4. Product Portfolio
    • 7.1.5. Business performance
  • 7.2. Allergan plc
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Operating business segments
    • 7.2.4. Product Portfolio
    • 7.2.5. Business performance
  • 7.3. Astellas Pharma Inc.
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Operating business segments
    • 7.3.4. Product Portfolio
    • 7.3.5. Business performance
  • 7.4. Boehringer Ingelheim Pharma GmbH & Co. KG
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Operating business segments
    • 7.4.4. Product Portfolio
    • 7.4.5. Business performance
  • 7.5. Eli Lilly and Company
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
    • 7.5.3. Operating business segments
    • 7.5.4. Product Portfolio
    • 7.5.5. Business performance
  • 7.6. GlaxoSmithKline plc.
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
    • 7.6.3. Operating business segments
    • 7.6.4. Product Portfolio
    • 7.6.5. Business performance
  • 7.7. Merck & Co., Inc.
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Operating business segments
    • 7.7.4. Product Portfolio
    • 7.7.5. Business performance
  • 7.8. Pfizer Inc.
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Operating business segments
    • 7.8.4. Product Portfolio
    • 7.8.5. Business performance
  • 7.9. Sanofi
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
    • 7.9.3. Operating business segments
    • 7.9.4. Product Portfolio
    • 7.9.5. Business performance
  • 7.10. Teva Pharmaceutical Industries Limited
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Operating business segments
    • 7.10.4. Product Portfolio
    • 7.10.5. Business performance
    • 7.10.6. Key strategic moves and developments

List of Tables

  • TABLE 01. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 02. GLOBAL ALPHA BLOCKERS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 03. GLOBAL 5-ALPHA REDUCTASE INHIBITORS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 04. GLOBAL PHOSPHODIESTERASE 5 INHIBITOR MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 05. GLOBAL OTHER BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 06. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 07. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET BY MONO DRUG THERAPY, BY REGION, 2017-2025 ($MILLION)
  • TABLE 08. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET BY COMBINATION DRUG THERAPY, BY REGION, 2017-2025 ($MILLION)
  • TABLE 09. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 10. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 11. U.S. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 12. U.S. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 13. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 14. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 15. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 16. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 17. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 18. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 19. EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 20. GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 21. GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 22. FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 23. FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 24. UK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 25. UK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 26. ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 27. ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 28. SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 29. SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 30. REST OF EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 31. REST OF EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 32. EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 33. EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 34. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 35. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 36. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 37. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 38. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 39. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 40. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 41. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 42. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 43. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 44. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 45. REST OF ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 46. REST OF ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 47. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 48. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 49. LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 50. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 51. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 52. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 53. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 54. SOUTH ARICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 55. SOUTH ARICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 56. REST OF LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 57. REST OF LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 58. LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
  • TABLE 59. LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 60. ABBOTT: COMPANY SNAPSHOT
  • TABLE 61. ABBOTT: OPERATING SEGMENTS
  • TABLE 62. ABBOTT: PRODUCT PORTFOLIO
  • TABLE 63. ALLERGAN: COMPANY SNAPSHOT
  • TABLE 64. ALLERGAN: OPERATING SEGMENTS
  • TABLE 65. ALLERGAN: PRODUCT PORTFOLIO
  • TABLE 66. ASTELLAS: COMPANY SNAPSHOT
  • TABLE 67. ASTELLAS: PRODUCTS AND SERVICES
  • TABLE 68. ASTELLAS: PRODUCT PORTFOLIO
  • TABLE 69. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 70. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
  • TABLE 71. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 72. LILLY: COMPANY SNAPSHOT
  • TABLE 73. LILLY: OPERATING SEGMENTS
  • TABLE 74. LILLY: PRODUCT PORTFOLIO
  • TABLE 75. GSK: COMPANY SNAPSHOT
  • TABLE 76. GSK: OPERATING SEGMENTS
  • TABLE 77. GSK: PRODUCT PORTFOLIO
  • TABLE 78. MERCK: COMPANY SNAPSHOT
  • TABLE 79. MERCK: OPERATING SEGMENTS
  • TABLE 80. MERCK: PRODUCT PORTFOLIO
  • TABLE 81. PFIZER: COMPANY SNAPSHOT
  • TABLE 82. PFIZER: OPERATING SEGMENTS
  • TABLE 83. PFIZER: PRODUCT PORTFOLIO
  • TABLE 84. SANOFI: COMPANY SNAPSHOT
  • TABLE 85. SANOFI: OPERATING SEGMENTS
  • TABLE 86. SANOFI: PRODUCT PORTFOLIO
  • TABLE 87. TEVA: COMPANY SNAPSHOT
  • TABLE 88. TEVA: OPERATING SEGMENTS
  • TABLE 89. TEVA: PRODUCT PORTFOLIO

List of Figures

  • FIGURE 01. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 02. TOP INVESTMENT POCKETS
  • FIGURE 03. TOP PLAYER POSITIONING, 2017
  • FIGURE 04. BARGANING POWER OF BUYERS
  • FIGURE 05. BARGANING POWER OF SUPPLIERS
  • FIGURE 06. THREAT OF SUBSTITUTION
  • FIGURE 07. THREAT OF NEW ENTRANT
  • FIGURE 08. COMPETITIVE RIVALRY
  • FIGURE 09. IMPACT ANALYSES
  • FIGURE 10. CLINICAL TRIALS IN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION
  • FIGURE 11. CLINICAL TRIALS IN BPH THERAPEUTICS MARKET, NORTH AMERICA
  • FIGURE 12. COMPARATIVE ANALYSIS OF ALPHA BLOCKERS MARKET, 2017 & 2025 (PERCENTAGE)
  • FIGURE 13. COMPARATIVE ANALYSIS OF 5-ALPHA REDUCTASE INHIBITORS MARKET, 2017 & 2025 (PERCENTAGE)
  • FIGURE 14. COMPARATIVE ANALYSIS OF PHOSPHODIESTERASE 5 INHIBITOR MARKET, 2017 & 2025 ($MILLION)
  • FIGURE 15. COMPARATIVE ANALYSIS OF OTHER BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, 2017 & 2025 ($MILLION)
  • FIGURE 16. COMPARATIVE ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET BY MONO DRUG THERAPY, 2017 & 2025 (PERCENTAGE)
  • FIGURE 17. COMPARATIVE ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET BY COMBINATION DRUG THERAPY, 2017 & 2025 (PERCENTAGE)
  • FIGURE 18. COMPARISON OF MALE GERIATRIC POPULATION IN EUROPEAN COUNTRIES FOR THE YEAR 2017, IN MILLION
  • FIGURE 19. ABBOTT: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 20. ABBOTT: NET SALES SHARE BY OPERATING SEGMENT, 2017 (%)
  • FIGURE 21. ABBOTT: NET SALES SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 22. ALLERGAN: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 23. ALLERGAN: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 24. ASTELLAS: SALES, 2015-2017 ($MILLION)
  • FIGURE 25. ASTELLAS: SALES SHARE BY PRODUCTS AND SERVICES, 2017 (%)
  • FIGURE 26. ASTELLAS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 27. BOEHRINGER INGELHEIM: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 28. BOEHRINGER INGELHEIM: NET SALES BY BUSINESS, 2017 (%)
  • FIGURE 29. BOEHRINGER INGELHEIM: NET SALES BY REGION, 2017 (%)
  • FIGURE 30. REVENUE, 2015-2017 ($MILLION)
  • FIGURE 31. LILLY: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 32. LILLY: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 33. GSK: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 34. GSK: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 35. GSK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 36. MERCK: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 37. MERCK: NET SALES BY SEGMENT, 2017 (%)
  • FIGURE 38. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)
  • FIGURE 39. PFIZER: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 40. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 41. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 42. SANOFI: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 43. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 44. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 45. TEVA: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 46. TEVA: REVENUE BY SEGMENT, 2017 (%)
  • FIGURE 47. TEVA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)